Phospho-DPYSL2 (T514) Antibody

What is DPYSL2/CRMP2 and why is its phosphorylation at T514 significant?

DPYSL2, also known as Collapsin Response Mediator Protein 2 (CRMP2), is a cytosolic protein that plays essential roles in neuronal development, particularly in axonal growth and guidance within the nervous system. The protein is primarily localized in the cytoplasm, membrane, cytoskeleton, and cytosol, with a calculated molecular weight of 62kDa (though it is observed at 69kDa on gels) .

Phosphorylation at threonine 514 (T514) is particularly significant because it functions as a regulatory mechanism that modulates CRMP2's activity in neuronal development and synaptic plasticity. This specific phosphorylation site is targeted by GSK3β after priming phosphorylation at Ser522 by CDK5, creating a regulatory cascade that controls axonal growth and neuronal connectivity . When CRMP2 becomes phosphorylated at T514, its ability to bind to tubulin is reduced, which affects microtubule assembly and ultimately influences axonal elongation and neuronal polarity. This phosphorylation event serves as a molecular switch that regulates CRMP2's function in the developing and mature nervous system .

How does Phospho-DPYSL2 (T514) Antibody differ from antibodies targeting other CRMP2 phosphorylation sites?

The Phospho-DPYSL2 (T514) Antibody specifically recognizes CRMP2 when phosphorylated at threonine 514, distinguishing it from antibodies targeting other phosphorylation sites such as Thr509, Ser522, or Thr555. This specificity allows researchers to investigate the distinct signaling pathways and functional outcomes associated with T514 phosphorylation. As shown in the comprehensive antibody table below, different antibodies are available for detecting various phosphorylation sites of CRMP2 :

The unique advantage of using a Phospho-DPYSL2 (T514)-specific antibody is that it enables researchers to specifically track GSK3β-mediated phosphorylation of CRMP2 without detecting other phosphorylation events, allowing for precise analysis of this particular regulatory mechanism in experimental settings .

What are the common experimental applications for Phospho-DPYSL2 (T514) Antibody?

Phospho-DPYSL2 (T514) Antibody is primarily used in the following experimental applications:

• Western Blotting: The antibody is extensively used for detecting T514-phosphorylated CRMP2 in protein lysates, with recommended dilutions ranging from 1:500 to 1:2000 . This application allows researchers to quantify changes in phosphorylation levels under various experimental conditions.

• ELISA (Enzyme-Linked Immunosorbent Assay): The antibody can be employed in ELISA-based assays to measure T514 phosphorylation levels in biological samples with high sensitivity .

• Immunohistochemistry: Although not explicitly mentioned in the provided data, phospho-specific CRMP2 antibodies are commonly used to visualize the distribution of phosphorylated CRMP2 in tissue sections from both normal and pathological samples.

• Cell-based assays: The antibody can be used to monitor changes in CRMP2 phosphorylation in response to pharmacological interventions, genetic manipulations, or disease models in cellular systems like SH-SY5Y neuroblastoma cells or PC-12 pheochromocytoma cells, which are listed as positive control samples for this antibody .

These applications help researchers investigate the roles of CRMP2 phosphorylation in neuronal development, neurodegenerative diseases, and various signaling pathways regulating neuronal function .

How is DPYSL2/CRMP2 phosphorylation implicated in neurodegenerative disorders?

DPYSL2/CRMP2 phosphorylation plays a significant role in several neurodegenerative conditions, with compelling evidence linking abnormal phosphorylation patterns to disease pathogenesis:

In Alzheimer's Disease (AD), CRMP2 becomes hyperphosphorylated as a result of dysregulated CDK5 activity . Phosphorylated CRMP2 has been found to associate with damaged neurites and neurofibrillary tangles in AD brains, and accumulates in neurons surrounding cortical amyloid plaques . This hyperphosphorylation likely contributes to cytoskeletal abnormalities and axonal transport defects characteristic of AD pathology.

In HIV-associated neurocognitive disorders, proteomics-based studies have identified differential expression of CRMP2 in brains from patients with HIV-encephalitis (HIVE) or HIV-associated dementia . Research has demonstrated that levels of both total and phosphorylated (Ser522) CRMP2 significantly increase in neurogenic sites of the hippocampus from HIVE patients compared to non-encephalitic HIV+ controls . Similar findings were observed in a mouse model of HIV-gp120 neurotoxicity, suggesting that CRMP2 phosphorylation may contribute to impaired neurogenesis and cognitive deficits in these conditions.

Additionally, emerging evidence links CRMP2 phosphorylation abnormalities to other neurodegenerative conditions including Parkinson's disease and amyotrophic lateral sclerosis, though these connections require further investigation. The Phospho-DPYSL2 (T514) Antibody provides researchers with a valuable tool to examine these disease-related alterations in CRMP2 phosphorylation and their consequences for neuronal function and survival .

What is the relationship between DPYSL2/CRMP2 phosphorylation and schizophrenia?

Multiple linkage and association studies have implicated DPYSL2 at chromosome 8p21.2 in schizophrenia risk, suggesting a potential connection between CRMP2 function and this psychiatric disorder . Functional genetic studies have identified several variants in and around the DPYSL2 gene that increase schizophrenia susceptibility, including:

• A three-SNP haplotype in the proximal promoter region

• Two SNPs in intron 1

• A polymorphic dinucleotide repeat (DNR) in the 5'-untranslated region that affects sequences involved in translational regulation by mammalian target of rapamycin (mTOR) signaling

Functional studies using luciferase reporter assays demonstrated that the high-risk allele of the polymorphic dinucleotide repeat diminished reporter expression by 3- to 4-fold compared to the low-risk allele . Both alleles responded to mTOR inhibition by rapamycin, though allelic differences were eliminated at high drug concentrations, suggesting that this variant affects mTOR-regulated translation of DPYSL2 .

Expression studies in postmortem brain tissue revealed that DPYSL2B expression correlated with the three-SNP promoter haplotype (with the high-risk haplotype showing greater expression), while DPYSL2A expression correlated with sex, age, and a SNP in the 3' flank of DPYSL2 . These findings suggest that schizophrenia-associated genetic variants may dysregulate DPYSL2 expression and potentially alter its phosphorylation patterns, which could disrupt neuronal development and connectivity relevant to schizophrenia pathophysiology .

How do different kinases regulate DPYSL2/CRMP2 phosphorylation at T514 and other sites?

CRMP2 phosphorylation is regulated by multiple kinases that target specific residues, creating a complex regulatory network that modulates CRMP2 function in different cellular contexts:

This hierarchical phosphorylation cascade allows for precise control of CRMP2 function in response to various signaling pathways. Dysregulation of these kinases, particularly CDK5 and GSK3β, has been implicated in neurodegenerative conditions where abnormal CRMP2 phosphorylation is observed . Understanding the specific contributions of each kinase to CRMP2 phosphorylation is essential for designing targeted therapeutic interventions aimed at modulating CRMP2 function in neurological disorders.

What are the optimal sample preparation methods for detecting phosphorylated DPYSL2/CRMP2?

For optimal detection of phosphorylated DPYSL2/CRMP2 using the Phospho-DPYSL2 (T514) Antibody, researchers should implement the following sample preparation methods:

• Rapid sample collection and processing: Phosphorylation states can change rapidly due to endogenous phosphatase activity. Tissues or cells should be quickly collected and immediately processed or flash-frozen in liquid nitrogen to preserve phosphorylation status.

• Phosphatase inhibitors: Sample lysis buffers should contain a comprehensive phosphatase inhibitor cocktail (e.g., sodium fluoride, sodium orthovanadate, β-glycerophosphate, and pyrophosphate) to prevent dephosphorylation during sample preparation.

• Protein extraction: For Western blotting applications, proteins can be extracted using RIPA buffer or similar lysis buffers containing protease and phosphatase inhibitors. For neuronal tissues specifically, gentle homogenization methods should be employed to maintain protein integrity.

• Sample handling: Keep samples on ice throughout the preparation process, and avoid repeated freeze-thaw cycles which can affect phosphoprotein stability.

• Positive controls: Include positive control samples such as lysates from SH-SY5Y or PC-12 cells, which are known to express phosphorylated CRMP2 at detectable levels .

• Quantification and loading: Standardize protein quantification and loading to ensure consistent results. For Western blotting, 20-50 μg of total protein per lane is typically sufficient for detection of phosphorylated CRMP2.

These precautions are essential for maintaining the phosphorylation state of CRMP2 and obtaining reliable, reproducible results when using the Phospho-DPYSL2 (T514) Antibody .

How should researchers validate the specificity of Phospho-DPYSL2 (T514) Antibody in their experimental system?

To ensure the validity of experimental results, researchers should rigorously validate the specificity of Phospho-DPYSL2 (T514) Antibody using the following approaches:

• Phosphatase treatment control: Treating one sample with lambda phosphatase prior to immunoblotting should eliminate the signal from the phospho-specific antibody while leaving total CRMP2 signal intact when probed with a total CRMP2 antibody. This confirms that the antibody specifically recognizes the phosphorylated form of the protein.

• Peptide competition assay: Pre-incubating the antibody with the phosphorylated peptide immunogen (the synthetic phosphorylated peptide around T514 of human CRMP2/DPYSL2) should block specific binding and eliminate the signal, while pre-incubation with the non-phosphorylated version of the same peptide should not affect antibody binding.

• Kinase inhibition/activation: Treating cells with specific inhibitors of GSK3β (which phosphorylates T514) should reduce the phospho-specific signal, while treatments that activate this kinase should increase it. Similarly, since CDK5-mediated phosphorylation of Ser522 primes for GSK3β phosphorylation of Thr514, manipulating CDK5 activity (e.g., with p35 overexpression) should indirectly affect Thr514 phosphorylation .

• Genetic approaches: Using siRNA knockdown or CRISPR/Cas9 knockout of DPYSL2/CRMP2 should eliminate both phosphorylated and total CRMP2 signals, confirming antibody specificity.

• Cross-reactivity assessment: Test for potential cross-reactivity with other CRMP family members (CRMP1 and CRMP4) that may share similar phosphorylation motifs . This is particularly important as the Thr514 site is relatively conserved across CRMP proteins.

• Multiple antibody verification: Compare results using antibodies from different sources that recognize the same phosphorylation site, such as the rabbit polyclonal antibody from Cell Signaling and the sheep polyclonal antibody from Kinasource, both targeting pThr514-CRMP2 .

These validation steps ensure that experimental observations genuinely reflect the phosphorylation status of CRMP2 at Thr514 rather than non-specific signals or artifacts.

What are the recommended experimental controls when studying DPYSL2/CRMP2 phosphorylation in disease models?

When investigating DPYSL2/CRMP2 phosphorylation in disease models, researchers should implement the following experimental controls to ensure robust and interpretable results:

• Total CRMP2 measurement: Always assess total CRMP2 levels in parallel with phosphorylated CRMP2 to distinguish between changes in phosphorylation state versus alterations in total protein expression. This requires using a separate antibody that recognizes CRMP2 regardless of its phosphorylation status .

• Multiple phosphorylation sites: Consider examining multiple phosphorylation sites on CRMP2 (Thr509, Thr514, Ser522, Thr555) to obtain a comprehensive picture of CRMP2 phosphorylation status and identify site-specific alterations in disease conditions .

• Kinase and phosphatase controls: Include experimental manipulations that alter the activity of relevant kinases (GSK3β, CDK5) and phosphatases to establish the expected range of phosphorylation changes. For example, researchers have used p35 overexpression (via adenoviral vector or plasmid transfection) to increase CDK5 activity and consequently enhance CRMP2 phosphorylation .

• Age and sex-matched controls: When using animal models or human samples, carefully match experimental and control groups for age and sex, as CRMP2 expression has been shown to be influenced by both factors. Studies have demonstrated higher CRMP2A expression in males and younger individuals, with a sex-specific age-related decline .

• Parallel assays: Employ complementary techniques such as Western blotting, immunohistochemistry, and mass spectrometry to corroborate findings related to CRMP2 phosphorylation in disease models.

• Time course analyses: Include time course experiments to capture dynamic changes in CRMP2 phosphorylation during disease progression rather than single time point measurements.

• Pathway validation: Confirm the involvement of relevant signaling pathways by demonstrating corresponding changes in upstream regulators (e.g., CDK5, GSK3β) and downstream effectors of CRMP2 phosphorylation .

These controls are particularly important when investigating neurodegenerative disorders where CRMP2 hyperphosphorylation has been implicated, such as Alzheimer's disease and HIV-associated neurocognitive disorders .

How can researchers address discrepancies between in vitro and in vivo DPYSL2/CRMP2 phosphorylation patterns?

Researchers frequently encounter discrepancies between in vitro and in vivo DPYSL2/CRMP2 phosphorylation patterns. To address and reconcile these differences:

• Context-dependent regulation: Recognize that CRMP2 phosphorylation is subject to complex regulatory mechanisms that may differ between simplified in vitro systems and the more complex in vivo environment. For example, studies have observed opposing directions of expression correlation with risk haplotypes between luciferase assays (showing decreased expression with high-risk haplotype) and postmortem brain tissue (showing increased expression with high-risk haplotype) .

• Multiple regulatory layers: Consider that in vivo systems contain additional regulatory layers affecting CRMP2 phosphorylation, including compensatory mechanisms, feedback loops, and cross-talk between signaling pathways that may be absent in vitro.

• Cell type specificity: Evaluate whether the cell types used for in vitro studies adequately recapitulate the cellular context relevant to your research question. Primary neurons might provide more physiologically relevant results than cell lines for neuronal studies. Studies have used both HEK293 cells and primary E14.5 cortical mouse neurons for in vitro assessments with different outcomes .

• Temporal dynamics: Consider the possibility that temporal dynamics of phosphorylation differ between in vitro and in vivo conditions. Time-course experiments in both systems can help identify potential temporal shifts in phosphorylation patterns.

• Technical validation: When discrepancies arise, validate findings using alternative techniques. For example, if Western blot results differ from immunohistochemistry, consider using phospho-proteomics or ELISA to provide additional perspectives.

• Microenvironment factors: Assess whether factors in the in vivo microenvironment (e.g., growth factors, cytokines, cell-cell interactions) might be influencing CRMP2 phosphorylation in ways not replicated in vitro.

• Genetic background effects: For studies in genetic models, consider whether the genetic background might influence CRMP2 phosphorylation patterns differently in vitro versus in vivo. Research has shown that genetic variants in DPYSL2 can affect its expression and potentially its phosphorylation .

By systematically addressing these factors, researchers can develop more nuanced interpretations of CRMP2 phosphorylation data and design experimental approaches that better bridge the gap between in vitro findings and in vivo relevance.

What strategies can overcome challenges in detecting subtle changes in DPYSL2/CRMP2 phosphorylation?

Detecting subtle changes in DPYSL2/CRMP2 phosphorylation can be challenging, particularly in complex biological samples. Researchers can employ the following strategies to enhance detection sensitivity and reliability:

• Quantitative Western blotting: Implement rigorous quantitative Western blotting protocols using internal loading controls and normalization to total CRMP2 levels. Digital imaging systems with wide dynamic ranges provide more accurate quantification than film-based detection.

• Phospho-enrichment techniques: Prior to analysis, use phosphoprotein enrichment methods such as phospho-specific antibody immunoprecipitation, metal oxide affinity chromatography (MOAC), or immobilized metal affinity chromatography (IMAC) to concentrate phosphorylated CRMP2 from complex samples.

• Mass spectrometry approaches: Employ targeted mass spectrometry techniques such as selected reaction monitoring (SRM) or parallel reaction monitoring (PRM) to quantify specific phosphopeptides with high sensitivity and specificity. These approaches can detect changes that may be below the detection threshold of antibody-based methods.

• Multiple phospho-epitope monitoring: Since CRMP2 contains several phosphorylation sites that are often modified in concert (Thr509, Thr514, Ser522, Thr555), monitoring multiple sites simultaneously can provide a more complete picture of subtle phosphorylation changes .

• Signal amplification methods: Consider using signal amplification techniques such as tyramide signal amplification for immunohistochemistry or enhanced chemiluminescence systems for Western blotting to detect low-abundance phosphorylated species.

• Increased biological replication: Increase the number of biological replicates to improve statistical power for detecting subtle changes. This is especially important when studying genetic variants with modest effects on CRMP2 phosphorylation.

• Cellular fractionation: Separate cellular compartments (cytosolic, membrane, cytoskeletal fractions) before analysis, as CRMP2 distributes across multiple cellular locations , and phosphorylation-dependent changes might be more readily detected in specific compartments.

• Kinase activity manipulation: Experimentally manipulate relevant kinase activities (e.g., CDK5, GSK3β) to transiently enhance phosphorylation signal differences between experimental conditions, potentially making subtle baseline differences more apparent .

By combining these approaches, researchers can substantially improve their ability to detect and quantify subtle but biologically significant changes in CRMP2 phosphorylation under various experimental conditions.

How should researchers interpret conflicting data on DPYSL2/CRMP2 phosphorylation in different experimental models?

When faced with conflicting data on DPYSL2/CRMP2 phosphorylation across different experimental models, researchers should employ the following interpretative framework:

• Model-specific biology: Consider that different models (cell lines, primary cultures, animal models, human tissues) may exhibit genuinely different CRMP2 phosphorylation patterns due to intrinsic biological differences. For instance, research has shown that CRMP2 phosphorylation patterns differ between various cell types and brain regions, reflecting cell-specific regulatory mechanisms .

• Species-specific differences: Recognize that while CRMP2 is highly conserved, species-specific differences exist. Zebrafish have two DPYSL2 paralogs (dpysl2a and dpysl2b) that are 87.1% identical to each other and 89.7% and 82.4% identical to the human ortholog, respectively . These differences may influence phosphorylation patterns and antibody reactivity.

• Developmental stage considerations: CRMP2 function and phosphorylation are developmentally regulated. Conflicting data may reflect differences in developmental timing between models. Studies have examined CRMP2 expression across different developmental stages (24 hpf, 48 hpf, 72 hpf, and 96 hpf) in zebrafish models, revealing stage-specific expression patterns .

• Technique-dependent outcomes: Different detection methods (Western blotting, immunohistochemistry, mass spectrometry) have distinct sensitivities, specificities, and potential artifacts. Cross-validate findings using multiple techniques before concluding that differences represent true biological variation.

• Contextual analysis: Interpret phosphorylation data within the broader signaling context by examining upstream kinases (CDK5, GSK3β) and downstream effects on CRMP2 function. For example, p35 overexpression experiments have demonstrated that CDK5 activation increases CRMP2 phosphorylation at Ser522, which then facilitates GSK3β-mediated phosphorylation at Thr514 .

• Triangulation approach: When faced with conflicting data, implement a triangulation approach using three or more distinct experimental systems to identify consistent patterns amid model-specific variations.

• Genetic and pharmacological validation: Use both genetic approaches (knockout/knockdown) and pharmacological interventions (kinase inhibitors) to validate the regulatory mechanisms governing CRMP2 phosphorylation across different models.

• Comprehensive phosphorylation profiling: Analyze multiple phosphorylation sites simultaneously to develop a comprehensive phosphorylation profile, which may reveal that different models exhibit distinct patterns of site-specific phosphorylation rather than uniform differences across all sites .